Related Experiment Video
Updated: May 21, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Analysis on 71 patients with polycythemia vera.
Chun-Hong Xin1, Jun-Qing Xu, Jing-Rui Sui
1Department of Hematology, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, Shandong Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|June 29, 2012
Summary
This study analyzed 71 polycythemia vera (PV) patients, finding thrombosis and hemorrhage are common. Elevated serum lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) levels correlate with disease severity and can indicate treatment effectiveness.
Area of Science:
- Hematology
- Oncology
Background:
- Polycythemia vera (PV) is a chronic myeloproliferative neoplasm.
- Understanding clinical characteristics, laboratory findings, and prognosis is crucial for patient management.
Purpose of the Study:
- To analyze the clinical characteristics, laboratory data, treatment, and prognosis of polycythemia vera.
- To investigate the correlation of serum lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) levels with disease parameters.
Main Methods:
- Retrospective analysis of 71 polycythemia vera patients.
- Inclusion of clinical data, laboratory results, myelogram chromosome karyotypes, BCR/ABL, JAK2V617F gene analysis, and serum LDH/NSE levels.
- Statistical analysis of correlations between variables.
Main Results:
- Thrombosis and embolism occurred in 47.89% of patients; hemorrhage in 14.08%.
- JAK2V617F mutation was detected in 81.58% of tested patients.
- Elevated serum LDH and NSE levels showed a positive correlation with hemoglobin (P = 0.007, P = 0.005).
Conclusions:
- Polycythemia vera is a chronic disorder primarily associated with thrombosis and hemorrhage.
- Serum LDH and NSE levels are elevated and may reflect bone marrow hematopoietic cell proliferation.
- Serum LDH and NSE can serve as indicators for assessing therapeutic effects in PV patients.
